Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis

IMPORTANCE: One of the most recent treatment regimens used for hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative metastatic breast cancer is treatment with the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and endocrine therapy (ET). OBJECTIVE: To assess overall survival (OS), pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Netw Open
Main Authors: Li, Jinming, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Ahmad, Raees, Yuan, Xinyue, Du, Feng, Zhao, Jiuda
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094425/
https://ncbi.nlm.nih.gov/pubmed/33048129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.20312
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados